ImageneBio (NASDAQ:IMA) Upgraded by HC Wainwright to Strong-Buy Rating

HC Wainwright upgraded shares of ImageneBio (NASDAQ:IMA) to a strong-buy rating in a research report released on Friday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. Wall Street Zen lowered ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $29.00.

ImageneBio Price Performance

NASDAQ:IMA opened at $5.51 on Friday. The firm has a 50-day moving average of $5.79 and a two-hundred day moving average of $5.86. The stock has a market cap of $62.54 million, a P/E ratio of -1.20 and a beta of 0.76. ImageneBio has a 1-year low of $3.94 and a 1-year high of $14.34.

ImageneBio (NASDAQ:IMA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. As a group, equities analysts expect that ImageneBio will post -3.07 earnings per share for the current year.

Institutional Investors Weigh In On ImageneBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Owl Capital Holdings LP acquired a new stake in shares of ImageneBio in the 2nd quarter valued at about $5,414,000. Deep Track Capital LP acquired a new position in ImageneBio in the third quarter worth about $7,160,000. Cable Car Capital LP bought a new stake in ImageneBio in the second quarter valued at about $4,611,000. Trails Edge Capital Partners LP bought a new stake in ImageneBio in the second quarter valued at about $1,663,824,000. Finally, Vanguard Group Inc. acquired a new stake in ImageneBio during the third quarter valued at approximately $1,902,000. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.